Background: The human gastrointestinal system is populated with a variety of symbiotic
microorganisms, namely microbiota. The microbiome is the total genetic data of the
microbiota. The human gut microbiota interacts extensively with the host through metabolic
exchange; thereby contribute to a variety of metabolic and immunologic mechanisms in the
human body. Coronary artery disease (CAD) is major cause of morbidity and mortality worldwide
and is a major field of interest in microbiota research. There have been several findings
that connect the gut microbiota to CAD pathophysiology, but these data relates solely to the
interaction between human gut microbiome and cardiovascular risk factors. As far as known ,
data regarding patients who already developed CAD is lacking.
Aims: To investigate gut microbiota of patients with CAD, thereby allowing the adjustment of
personalized treatment by changing the pro-atherosclerotic environment in the gut.
Methods: Study participants will include patients arriving to Rabin Medical Center with
suspected CAD. Patients will provide medical, lifestyle, and nutritional questionnaires.
Vital signs measurements will be taken as well as fecal samples and/or rectal swabs. Blood
samples will be drawn to measure blood chemistry including lipid profile and
trimethylamine-N-oxide (TMAO) levels. Patients will undergo cardiac CT and/or cardiac
catheterization in accordance with the decision of the cardiologist to evaluate and/or treat
CAD. Genomic DNA will be extracted from stool samples for Microbiome analysis.
Innovation: The hypothesis is that there is a unique microbiota pattern in patients with
coronary atherosclerosis, which may contribute to the pathogenesis and/or expression of CAD.
Knowing the unique microbiota in patients with coronary disease, would render it as novel
target for treatment, either primary or secondary prevention.
Collaboration: Between Cardiology department at Rabin Medical Center and the lab of Prof.
Eran Segal located at the Weizmann Institute of Science. The collaboration between these two
groups will combine the clinical expertise of treating cardiac patients with novel scientific
technology and concept.